Morgan Stanley
PRVL

Morgan Stanley’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Morgan Stanley’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,936
Closed -$506K – 7710
2020
Q4 		$506K Sell
21,936
-619,970
-97% -$7.86M ﹤0.01% 5074
2020
Q3 		$6.54M Buy
641,906
+273,002
+74% +$3.66M ﹤0.01% 2455
2020
Q2 		$5.5M Buy
368,904
+292,096
+380% +$4.5M ﹤0.01% 2564
2020
Q1 		$937K Buy
76,808
+63,847
+493% +$1.02M ﹤0.01% 4006
2019
Q4 		$206K Buy
12,961
+8,655
+201% +$110K ﹤0.01% 5401
2019
Q3 		$53K Sell
4,306
-8,232
-66% -$93.3K ﹤0.01% 5707
2019
Q2 		$166K Buy
+12,538
New +$183K ﹤0.01% 5104

Morgan Stanley's PRVL Position: Q1 2021 in Review

Morgan Stanley sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 21,936 shares — an estimated $506K sold.

Morgan Stanley first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $6.54M in Q3 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Morgan Stanley reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Morgan Stanley sold 21,936 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $506K.
  • Morgan Stanley first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Morgan Stanley's Prevail Therapeutics Inc. Common Stock position peaked at $6.54M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.